atexakin alfa

Atexakin alfa is a low-dose, recombinant human interleukin 6 (IL-6), a cytokine with pleiotropic functions in various tissues and organs. It was originally developed by Merck KGaA and later licensed to Relief Therapeutics, then acquired by Sonnet BioTherapeutics. Atexakin alfa is being investigated primarily for the treatment of peripheral neuropathies, including chemotherapy-induced peripheral neuropathy (CIPN) and diabetic peripheral neuropathy (DPN). Its mechanism involves acting as an agonist at the interleukin 6 receptor alpha subunit, promoting nerve regeneration, remyelination, and reduction of neuropathic symptoms. Preclinical studies have shown it can induce regrowth of nerves and restore normal nerve conduction in animal models. Clinical trials have established its safety profile in hundreds of patients across cancer, diabetes, idiopathic aplastic anemia, and healthy controls[1][2][4][5][7][8].

Brand names

SON-080SON080SON 080

Other names

recombinant interleukin 6recombinant IL-6recombinant human interleukin 6rhIL-6rhIL6rhIL 6